4th Mar 2019 10:12
LONDON (Alliance News) - Shares in Verona Pharma PLC rose on Monday following positive data from part of a Phase Two clinical trial of a dry powder inhaler formulation of Verona's ensifentrine treatment.
Shares in the biopharmaceutical company were 10% higher at 56.90 pence on Monday.
Positive efficacy and safety data were reported from the first of a two-part clinical trial of ensifentrine in patients with moderate-to-severe chronic obstructive pulmonary diseases.
In the first part of the trial, 37 patients with COPD were given a single dose of one of five different dosages of ensifentrine or placebo, revealing a significant increase in lung function measured by forced expiratory volume in one second compared to placebo.
The positive data supports the start of the second part of the phase two trial, to evaluate the DPI formulation of ensifentrine in patients with moderate-to-severe COPD over one week of twice-daily treatment.
Related Shares:
VRP.L